Roots of clinical resistance to STI-571 cancer therapy.

STI-571, a new Abl tyrosine kinase inhibitor recently approved by the Food and Drug Administration, is highly effective in treating the early stages of chronic myeloid leukemia (CML), but remissions induced in advanced phases tend to be relatively short-lived, an observation that suggests the

[1]  C. Sawyers,et al.  Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells , 1998, Molecular and Cellular Biology.

[2]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[3]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.

[4]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[5]  M. Zucchetti,et al.  Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .

[6]  E. Sausville.  Dragons 'Round the Fleece Again: STI571 Versus α1 Acid Glycoprotein , 2000 .

[7]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[8]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[9]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.